0
Pulmonary Vascular Disease: Cystic Fibrosis |

Cancer Risks in Heterozygous Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) DelF508 Carriers

Jaya Prakash Sugunaraj, MD; Uyenlinh Mirshahi, PhD; Amr Wardeh, BS; Catarina Manney, BA; Kandamurugu Manickam, MD; Michael Murray, MD; David Carey, PhD; Jason Stamm, MD
Author and Funding Information

Geisinger Medical Center, Danville, PA


Copyright 2016, American College of Chest Physicians. All Rights Reserved.


Chest. 2016;150(4_S):1132A. doi:10.1016/j.chest.2016.08.1242
Text Size: A A A
Published online

Extract

SESSION TITLE: Cystic Fibrosis

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 26, 2016 at 01:30 PM - 02:30 PM

PURPOSE: The Cystic Fibrosis Transmembrane conductance Regulator (CFTR) delF508 variant, which is responsible for 86% of cystic fibrosis (CF) cases, is present in Caucasian populations at a frequency of 3-5%. The vast majority of CFTR delF508 carriers do not have CF. There is little information on health and disease in heterozygous delF508 individuals. Previous studies have suggested risk-enhancing and risk-reducing effects for various diseases, with sometimes conflicting conclusions. Our aims are to determine if heterozygous delF508, in the absence of CF, is associated with risks for certain cancers. We took a genotype-first approach in a retrospective exploratory case-control study to determine cancer risks of delF508 carriers. We tested this using a unique database of 50,778 whole exome sequences (WES) linked to the extensive electronic health record (EHR) data of patients of Geisinger Health System who consented to participate in the MyCode Community Health Initiative biobanking project.

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543